medscape.com
Cure8 news brief
FDA OKs Guselkumab for Crohn's Disease - Medscape
Medications
Guselkumab
IL-23 inhibitor
FDA Approval
Adult patients
Patients On Biologics
Clinicians
Researchers
Why This Matters
An FDA approval means guselkumab (Tremfya) is now an approved treatment option for adults with moderate-to-severe Crohn’s disease, including a unique option for fully subcutaneous induction. This may expand choices for patients who have not responded to other therapies.
Who Should Pay Attention
Adults with moderate-to-severe Crohn’s disease, patients who failed prior biologics or immunomodulators, clinicians treating IBD, and researchers interested in IL-23 therapies.
Study Snapshot
Story typeResearch news
Evidence typeFDA Approval
Source depthFull source text
What To Know
Guselkumab is now an FDA-approved IL-23 inhibitor option for adults with moderate to severe Crohn’s disease. The approval expands treatment choices and is notable because it offers both IV and fully subcutaneous induction approaches.
If you are already on biologic therapy or have failed other therapies, this approval may be relevant; talk with your clinician about whether this option fits your situation.
Keep In Mind
Approval is based on phase 3 trials reported by the company and summarized in the article; consult the full prescribing information and discuss risks and benefits with a clinician. The article is a news summary and draws on company statements and trial names rather than providing full primary data.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationmedscape.com
Indexed viaGoogle News
Source typeResearch news
PublishedMar 25, 2025, 7:04 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
J&J secures FDA approval for Tremfya to treat Crohn's disease
An FDA approval means guselkumab (Tremfya) is now an authorized treatment option for adults with active Crohn’s disease. The drug offers both subcutaneous and IV induction choices and may be relevant for people who did...
Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease
A new FDA approval expands treatment options for adults with moderately to severely active Crohn’s disease, including a fully subcutaneous IL-23 inhibitor regimen that could offer more flexibility. The approval was based...
FDA Approves TREMFYA® for Crohn’s Disease, Offering New Treatment Options
Based on the title and source metadata, this appears to be a fda approval related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from msn.com.